Worldwide human papillomavirus genotype attribution in over 2000 cases of intraepithelial and invasive lesions of the vulva

Silvia De Sanjosé; Laia Alemany; Jaume Ordi; Sara Tous; Maria Alejo; Susan M. Bigby; Elmar Armin Joura; Paula Maldonado; Jan Laco; Ignacio G. Bravo; August Vidal; Núria Guimerà; Paul Cross; Gerard V. Wain; Karl Ulrich Petry; Luciano Mariani; Christine Bergeron; Václav Mandys; Adela Rosa Sica; Ana Félix; Alp Usubutun; Muhieddine Seoud; Gustavo Hernández-Suárez; Andrzej Marcin Nowakowski; Godfrey Wilson; Veronique Dalstein; Monika Hampl; Elena Sachiko Kasamatsu; Luis Estuardo Lombardi; Leopoldo Tinoco; Isabel Alvarado-Cabrero; Myriam Perrotta; Neerja Bhatla; Theodoros Agorastos; Charles F. Lynch; Marc T. Goodman; Hai Rim Shin; Halina Viarheichyk; Robert Jach; M. O.L.Eugenia Cruz; Julio Velasco; Carla Molina; Jacob Bornstein; Annabelle Ferrera; Efren Javier Domingo; Cheng Yang Chou; Adekunbiola F. Banjo; Xavier Castellsagué; Michael Pawlita; Belén Lloveras; Wim G.V. Quint; Nubia Muñoz; F. Xavier Bosch

doi:10.1016/j.ejca.2013.06.033

Worldwide human papillomavirus genotype attribution in over 2000 cases of intraepithelial and invasive lesions of the vulva

Silvia De Sanjosé
, Laia Alemany
, Jaume Ordi
, Sara Tous
, Maria Alejo
, Susan M. Bigby
, Elmar Armin Joura
, Paula Maldonado
, Jan Laco
, Ignacio G. Bravo
, August Vidal
, Núria Guimerà
, Paul Cross
, Gerard V. Wain
, Karl Ulrich Petry
, Luciano Mariani
, Christine Bergeron
, Václav Mandys
, Adela Rosa Sica
, Ana Félix

Alp Usubutun, Muhieddine Seoud, Gustavo Hernández-Suárez, Andrzej Marcin Nowakowski, Godfrey Wilson, Veronique Dalstein, Monika Hampl, Elena Sachiko Kasamatsu, Luis Estuardo Lombardi, Leopoldo Tinoco, Isabel Alvarado-Cabrero, Myriam Perrotta, Neerja Bhatla, Theodoros Agorastos, Charles F. Lynch, Marc T. Goodman, Hai Rim Shin, Halina Viarheichyk, Robert Jach, M. O.L.Eugenia Cruz, Julio Velasco, Carla Molina, Jacob Bornstein, Annabelle Ferrera, Efren Javier Domingo, Cheng Yang Chou, Adekunbiola F. Banjo, Xavier Castellsagué, Michael Pawlita, Belén Lloveras, Wim G.V. Quint, Nubia Muñoz, F. Xavier Bosch

Bar-Ilan University - Azrieli Faculty of Medicine

Institute Catala Oncologia
Centro de Investigación Biomédica en Red
University of Barcelona
Hospital General d'Hospitalet
Middlemore Hospital
Medical University of Vienna
Universidade Federal do Rio de Janeiro
Charles University
Hospital Universitari de Bellvitge
DDL Diagnostic Laboratory
Gateshead Health NHS Foundation Trust
Westmead Hospital
Klinikum Wolfsburg
IRCCS Istituti fisioterapici ospitalieri - Istituto Regina Elena
Laboratoire Pasteur Cerba
Laboratorio de Anatomía Patológica Del Hospital de la Mujer
Instituto Português de Oncologia de Lisboa Francisco Gentil E.P.E.
Hacettepe University
American University of Beirut
Instituto Nacional de Cancerología - Colombia
Medical University of Lublin
Manchester University NHS Foundation Trust
CHU de Reims
Heinrich Heine University Düsseldorf
Universidad Nacional de Asunción
Hospital General San Juan de Dios
Hospital Oncológico Solca Quito
Instituto Mexicano del Seguro Social
Hospital Italiano de Buenos Aires
All India Institute of Medical Sciences, New Delhi
Aristotle University of Thessaloniki
University of Iowa
University of Hawai'i at Mānoa
National Cancer Center Korea
Gomel State Medical University
Collegium Medicum Jagiellonian University
Centro Regional de Oncologia Coimbra
Hospital San Agustin
Universidad de Chile
National Autonomous University of Honduras
University of the Philippines
National Cheng Kung University
Lagos University Teaching Hospital
German Cancer Research Center
Hospital del Mar
Universidad del Valle

Research output: Contribution to journal › Article › peer-review

337 Scopus citations

Abstract

Background Human papillomavirus (HPV) contribution in vulvar intraepithelial lesions (VIN) and invasive vulvar cancer (IVC) is not clearly established. This study provides novel data on HPV markers in a large series of VIN and IVC lesions. Methods Histologically confirmed VIN and IVC from 39 countries were assembled at the Catalan Institute of Oncology (ICO). HPV-DNA detection was done by polymerase chain reaction using SPF-10 broad-spectrum primers and genotyping by reverse hybridisation line probe assay (LiPA ₂₅) (version 1). IVC cases were tested for p16^INK4a by immunohistochemistry (CINtec histology kit, ROCHE). An IVC was considered HPV driven if both HPV-DNA and p16^INK4a overexpression were observed simultaneously. Data analyses included algorithms allocating multiple infections to calculate type-specific contribution and logistic regression models to estimate adjusted prevalence (AP) and its 95% confidence intervals (CI). Results Of 2296 cases, 587 were VIN and 1709 IVC. HPV-DNA was detected in 86.7% and 28.6% of the cases respectively. Amongst IVC cases, 25.1% were both HPV-DNA and p16^INK4a positive. IVC cases were largely keratinising squamous cell carcinoma (KSCC) (N = 1234). Overall prevalence of HPV related IVC cases was highest in younger women for any histological subtype. SCC with warty or basaloid features (SCC-WB) (N = 326) were more likely to be HPV and p16 ^INK4a positive (AP = 69.5%, CI = 63.6-74.8) versus KSCC (AP = 11.5%, CI = 9.7-13.5). HPV 16 was the commonest type (72.5%) followed by HPV 33 (6.5%) and HPV 18 (4.6%). Enrichment from VIN to IVC was significantly high for HPV 45 (8.5-fold). Conclusion Combined data from HPV-DNA and p16^INK4a testing are likely to represent a closer estimate of the real fraction of IVC induced by HPV. Our results indicate that HPV contribution in invasive vulvar cancer has probably been overestimated. HPV 16 remains the major player worldwide.

Original language	English
Pages (from-to)	3450-3461
Number of pages	12
Journal	European Journal of Cancer
Volume	49
Issue number	16
DOIs	https://doi.org/10.1016/j.ejca.2013.06.033
State	Published - Nov 2013

Bibliographical note

Funding Information:
The corresponding author has received occasional travel grants from Merck and Qiagen and holds a restricted grant from Qiagen and from Merck not related to the study presented. The senior author F. Xavier Bosch is in the Advisory Board (Merck and Co., Inc.); Speakers Bureau (GlaxoSmithKline); has received Institutional Research Grants (Merck and Co., Inc., Sanofi Pasteur MSD, GlaxoSmithKline).

Funding

The corresponding author has received occasional travel grants from Merck and Qiagen and holds a restricted grant from Qiagen and from Merck not related to the study presented. The senior author F. Xavier Bosch is in the Advisory Board (Merck and Co., Inc.); Speakers Bureau (GlaxoSmithKline); has received Institutional Research Grants (Merck and Co., Inc., Sanofi Pasteur MSD, GlaxoSmithKline).

Funders
Merck and Qiagen
Merck

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Papillomavirus
Vulva
p16

Access to Document

10.1016/j.ejca.2013.06.033

Cite this

De Sanjosé, S., Alemany, L., Ordi, J., Tous, S., Alejo, M., Bigby, S. M., Joura, E. A., Maldonado, P., Laco, J., Bravo, I. G., Vidal, A., Guimerà, N., Cross, P., Wain, G. V., Petry, K. U., Mariani, L., Bergeron, C., Mandys, V., Sica, A. R., ... Bosch, F. X. (2013). Worldwide human papillomavirus genotype attribution in over 2000 cases of intraepithelial and invasive lesions of the vulva. European Journal of Cancer, 49(16), 3450-3461. https://doi.org/10.1016/j.ejca.2013.06.033

@article{ee37c2e42d0147ba80202bdd10165419,

title = "Worldwide human papillomavirus genotype attribution in over 2000 cases of intraepithelial and invasive lesions of the vulva",

abstract = "Background Human papillomavirus (HPV) contribution in vulvar intraepithelial lesions (VIN) and invasive vulvar cancer (IVC) is not clearly established. This study provides novel data on HPV markers in a large series of VIN and IVC lesions. Methods Histologically confirmed VIN and IVC from 39 countries were assembled at the Catalan Institute of Oncology (ICO). HPV-DNA detection was done by polymerase chain reaction using SPF-10 broad-spectrum primers and genotyping by reverse hybridisation line probe assay (LiPA 25) (version 1). IVC cases were tested for p16INK4a by immunohistochemistry (CINtec histology kit, ROCHE). An IVC was considered HPV driven if both HPV-DNA and p16INK4a overexpression were observed simultaneously. Data analyses included algorithms allocating multiple infections to calculate type-specific contribution and logistic regression models to estimate adjusted prevalence (AP) and its 95\% confidence intervals (CI). Results Of 2296 cases, 587 were VIN and 1709 IVC. HPV-DNA was detected in 86.7\% and 28.6\% of the cases respectively. Amongst IVC cases, 25.1\% were both HPV-DNA and p16INK4a positive. IVC cases were largely keratinising squamous cell carcinoma (KSCC) (N = 1234). Overall prevalence of HPV related IVC cases was highest in younger women for any histological subtype. SCC with warty or basaloid features (SCC-WB) (N = 326) were more likely to be HPV and p16 INK4a positive (AP = 69.5\%, CI = 63.6-74.8) versus KSCC (AP = 11.5\%, CI = 9.7-13.5). HPV 16 was the commonest type (72.5\%) followed by HPV 33 (6.5\%) and HPV 18 (4.6\%). Enrichment from VIN to IVC was significantly high for HPV 45 (8.5-fold). Conclusion Combined data from HPV-DNA and p16INK4a testing are likely to represent a closer estimate of the real fraction of IVC induced by HPV. Our results indicate that HPV contribution in invasive vulvar cancer has probably been overestimated. HPV 16 remains the major player worldwide.",

keywords = "Papillomavirus, Vulva, p16",

author = "\{De Sanjos{\'e}\}, Silvia and Laia Alemany and Jaume Ordi and Sara Tous and Maria Alejo and Bigby, \{Susan M.\} and Joura, \{Elmar Armin\} and Paula Maldonado and Jan Laco and Bravo, \{Ignacio G.\} and August Vidal and N{\'u}ria Guimer{\`a} and Paul Cross and Wain, \{Gerard V.\} and Petry, \{Karl Ulrich\} and Luciano Mariani and Christine Bergeron and V{\'a}clav Mandys and Sica, \{Adela Rosa\} and Ana F{\'e}lix and Alp Usubutun and Muhieddine Seoud and Gustavo Hern{\'a}ndez-Su{\'a}rez and Nowakowski, \{Andrzej Marcin\} and Godfrey Wilson and Veronique Dalstein and Monika Hampl and Kasamatsu, \{Elena Sachiko\} and Lombardi, \{Luis Estuardo\} and Leopoldo Tinoco and Isabel Alvarado-Cabrero and Myriam Perrotta and Neerja Bhatla and Theodoros Agorastos and Lynch, \{Charles F.\} and Goodman, \{Marc T.\} and Shin, \{Hai Rim\} and Halina Viarheichyk and Robert Jach and Cruz, \{M. O.L.Eugenia\} and Julio Velasco and Carla Molina and Jacob Bornstein and Annabelle Ferrera and Domingo, \{Efren Javier\} and Chou, \{Cheng Yang\} and Banjo, \{Adekunbiola F.\} and Xavier Castellsagu{\'e} and Michael Pawlita and Bel{\'e}n Lloveras and Quint, \{Wim G.V.\} and Nubia Mu{\~n}oz and Bosch, \{F. Xavier\}",

note = "Funding Information: The corresponding author has received occasional travel grants from Merck and Qiagen and holds a restricted grant from Qiagen and from Merck not related to the study presented. The senior author F. Xavier Bosch is in the Advisory Board (Merck and Co., Inc.); Speakers Bureau (GlaxoSmithKline); has received Institutional Research Grants (Merck and Co., Inc., Sanofi Pasteur MSD, GlaxoSmithKline). ",

year = "2013",

month = nov,

doi = "10.1016/j.ejca.2013.06.033",

language = "אנגלית",

volume = "49",

pages = "3450--3461",

journal = "European Journal of Cancer",

issn = "0959-8049",

publisher = "Elsevier Ltd.",

number = "16",

}

De Sanjosé, S, Alemany, L, Ordi, J, Tous, S, Alejo, M, Bigby, SM, Joura, EA, Maldonado, P, Laco, J, Bravo, IG, Vidal, A, Guimerà, N, Cross, P, Wain, GV, Petry, KU, Mariani, L, Bergeron, C, Mandys, V, Sica, AR, Félix, A, Usubutun, A, Seoud, M, Hernández-Suárez, G, Nowakowski, AM, Wilson, G, Dalstein, V, Hampl, M, Kasamatsu, ES, Lombardi, LE, Tinoco, L, Alvarado-Cabrero, I, Perrotta, M, Bhatla, N, Agorastos, T, Lynch, CF, Goodman, MT, Shin, HR, Viarheichyk, H, Jach, R, Cruz, MOLE, Velasco, J, Molina, C, Bornstein, J, Ferrera, A, Domingo, EJ, Chou, CY, Banjo, AF, Castellsagué, X, Pawlita, M, Lloveras, B, Quint, WGV, Muñoz, N & Bosch, FX 2013, 'Worldwide human papillomavirus genotype attribution in over 2000 cases of intraepithelial and invasive lesions of the vulva', European Journal of Cancer, vol. 49, no. 16, pp. 3450-3461. https://doi.org/10.1016/j.ejca.2013.06.033

TY - JOUR

T1 - Worldwide human papillomavirus genotype attribution in over 2000 cases of intraepithelial and invasive lesions of the vulva

AU - De Sanjosé, Silvia

AU - Alemany, Laia

AU - Ordi, Jaume

AU - Tous, Sara

AU - Alejo, Maria

AU - Bigby, Susan M.

AU - Joura, Elmar Armin

AU - Maldonado, Paula

AU - Laco, Jan

AU - Bravo, Ignacio G.

AU - Vidal, August

AU - Guimerà, Núria

AU - Cross, Paul

AU - Wain, Gerard V.

AU - Petry, Karl Ulrich

AU - Mariani, Luciano

AU - Bergeron, Christine

AU - Mandys, Václav

AU - Sica, Adela Rosa

AU - Félix, Ana

AU - Usubutun, Alp

AU - Seoud, Muhieddine

AU - Hernández-Suárez, Gustavo

AU - Nowakowski, Andrzej Marcin

AU - Wilson, Godfrey

AU - Dalstein, Veronique

AU - Hampl, Monika

AU - Kasamatsu, Elena Sachiko

AU - Lombardi, Luis Estuardo

AU - Tinoco, Leopoldo

AU - Alvarado-Cabrero, Isabel

AU - Perrotta, Myriam

AU - Bhatla, Neerja

AU - Agorastos, Theodoros

AU - Lynch, Charles F.

AU - Goodman, Marc T.

AU - Shin, Hai Rim

AU - Viarheichyk, Halina

AU - Jach, Robert

AU - Cruz, M. O.L.Eugenia

AU - Velasco, Julio

AU - Molina, Carla

AU - Bornstein, Jacob

AU - Ferrera, Annabelle

AU - Domingo, Efren Javier

AU - Chou, Cheng Yang

AU - Banjo, Adekunbiola F.

AU - Castellsagué, Xavier

AU - Pawlita, Michael

AU - Lloveras, Belén

AU - Quint, Wim G.V.

AU - Muñoz, Nubia

AU - Bosch, F. Xavier

N1 - Funding Information: The corresponding author has received occasional travel grants from Merck and Qiagen and holds a restricted grant from Qiagen and from Merck not related to the study presented. The senior author F. Xavier Bosch is in the Advisory Board (Merck and Co., Inc.); Speakers Bureau (GlaxoSmithKline); has received Institutional Research Grants (Merck and Co., Inc., Sanofi Pasteur MSD, GlaxoSmithKline).

PY - 2013/11

Y1 - 2013/11

N2 - Background Human papillomavirus (HPV) contribution in vulvar intraepithelial lesions (VIN) and invasive vulvar cancer (IVC) is not clearly established. This study provides novel data on HPV markers in a large series of VIN and IVC lesions. Methods Histologically confirmed VIN and IVC from 39 countries were assembled at the Catalan Institute of Oncology (ICO). HPV-DNA detection was done by polymerase chain reaction using SPF-10 broad-spectrum primers and genotyping by reverse hybridisation line probe assay (LiPA 25) (version 1). IVC cases were tested for p16INK4a by immunohistochemistry (CINtec histology kit, ROCHE). An IVC was considered HPV driven if both HPV-DNA and p16INK4a overexpression were observed simultaneously. Data analyses included algorithms allocating multiple infections to calculate type-specific contribution and logistic regression models to estimate adjusted prevalence (AP) and its 95% confidence intervals (CI). Results Of 2296 cases, 587 were VIN and 1709 IVC. HPV-DNA was detected in 86.7% and 28.6% of the cases respectively. Amongst IVC cases, 25.1% were both HPV-DNA and p16INK4a positive. IVC cases were largely keratinising squamous cell carcinoma (KSCC) (N = 1234). Overall prevalence of HPV related IVC cases was highest in younger women for any histological subtype. SCC with warty or basaloid features (SCC-WB) (N = 326) were more likely to be HPV and p16 INK4a positive (AP = 69.5%, CI = 63.6-74.8) versus KSCC (AP = 11.5%, CI = 9.7-13.5). HPV 16 was the commonest type (72.5%) followed by HPV 33 (6.5%) and HPV 18 (4.6%). Enrichment from VIN to IVC was significantly high for HPV 45 (8.5-fold). Conclusion Combined data from HPV-DNA and p16INK4a testing are likely to represent a closer estimate of the real fraction of IVC induced by HPV. Our results indicate that HPV contribution in invasive vulvar cancer has probably been overestimated. HPV 16 remains the major player worldwide.

AB - Background Human papillomavirus (HPV) contribution in vulvar intraepithelial lesions (VIN) and invasive vulvar cancer (IVC) is not clearly established. This study provides novel data on HPV markers in a large series of VIN and IVC lesions. Methods Histologically confirmed VIN and IVC from 39 countries were assembled at the Catalan Institute of Oncology (ICO). HPV-DNA detection was done by polymerase chain reaction using SPF-10 broad-spectrum primers and genotyping by reverse hybridisation line probe assay (LiPA 25) (version 1). IVC cases were tested for p16INK4a by immunohistochemistry (CINtec histology kit, ROCHE). An IVC was considered HPV driven if both HPV-DNA and p16INK4a overexpression were observed simultaneously. Data analyses included algorithms allocating multiple infections to calculate type-specific contribution and logistic regression models to estimate adjusted prevalence (AP) and its 95% confidence intervals (CI). Results Of 2296 cases, 587 were VIN and 1709 IVC. HPV-DNA was detected in 86.7% and 28.6% of the cases respectively. Amongst IVC cases, 25.1% were both HPV-DNA and p16INK4a positive. IVC cases were largely keratinising squamous cell carcinoma (KSCC) (N = 1234). Overall prevalence of HPV related IVC cases was highest in younger women for any histological subtype. SCC with warty or basaloid features (SCC-WB) (N = 326) were more likely to be HPV and p16 INK4a positive (AP = 69.5%, CI = 63.6-74.8) versus KSCC (AP = 11.5%, CI = 9.7-13.5). HPV 16 was the commonest type (72.5%) followed by HPV 33 (6.5%) and HPV 18 (4.6%). Enrichment from VIN to IVC was significantly high for HPV 45 (8.5-fold). Conclusion Combined data from HPV-DNA and p16INK4a testing are likely to represent a closer estimate of the real fraction of IVC induced by HPV. Our results indicate that HPV contribution in invasive vulvar cancer has probably been overestimated. HPV 16 remains the major player worldwide.

KW - Papillomavirus

KW - Vulva

KW - p16

UR - https://www.scopus.com/pages/publications/84885175699

U2 - 10.1016/j.ejca.2013.06.033

DO - 10.1016/j.ejca.2013.06.033

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???

C2 - 23886586

AN - SCOPUS:84885175699

SN - 0959-8049

VL - 49

SP - 3450

EP - 3461

JO - European Journal of Cancer

JF - European Journal of Cancer

IS - 16

ER -

Worldwide human papillomavirus genotype attribution in over 2000 cases of intraepithelial and invasive lesions of the vulva

Abstract

Bibliographical note

Funding

UN SDGs

Keywords

Access to Document

Other files and links

Fingerprint

Cite this